Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma.
Targeting a pathway that is essential for the survival of certain types of acute myeloid leukaemia could provide a new therapy avenue for patients, researchers from Wellcome Sanger Institute found.
Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute received a $2.08 million grant from NCI to research whether Black and white cancer patients respond differently to immune checkpoint inhibitors.
City of Hope scientists have developed a novel, noninvasive liquid biopsy test for detecting lymph node metastasis in individuals with high-risk T1 colorectal carcinoma.
Yale Cancer Center researchers have discovered a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Mantle cell lymphoma.
Yale Cancer Center Researchers have discovered a new role for the STimulator of INterferon Genes, or STING.
A test which uses artificial intelligence to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment.
Patients with early-onset colorectal cancer, age 50 and younger, have a better survival rate than patients diagnosed with the disease later in life, a study by Yale Cancer Center researchers shows.
Patients with non-small cell lung cancer (whose cancer cells have low levels of—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers found.
Early results from a chimeric antigen receptor T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional single-target approach helps minimizes treatment resistance, resulting in long-lasting remission for people with non-Hodgkin’s B-cell lymphoma that has come back or has not responded to treatment.
